<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16296">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894736</url>
  </required_header>
  <id_info>
    <org_study_id>HC15010</org_study_id>
    <nct_id>NCT02894736</nct_id>
  </id_info>
  <brief_title>Home-Administered Trial of Direct Current Stimulation</brief_title>
  <acronym>HAT-DCS</acronym>
  <official_title>Home-administered Transcranial Direct Current Stimulation (tDCS) Treatment for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of New South Wales</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial Direct Current Stimulation (tDCS) is a novel non-invasive brain stimulation
      treatment that is effective with no significant side effects. It can potentially be
      self-administered by patients in their own homes with remote monitoring, substantially
      reducing treatment costs and increasing accessibility, including to remote areas. This study
      will evaluate the feasibility and efficacy of home-administered tDCS treatment for
      depression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale for Depression (MADRS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soterix tDCS machine is used to administer active stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soterix tDCS machine</intervention_name>
    <description>Soterix tDCS machine - miniCT supervised neuromodulation system</description>
    <arm_group_label>Active tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject meets criteria for a DSM-IV Major Depressive Episode, lasting more than 4
             weeks

          -  Total MADRS score â‰¥ 20

        Exclusion Criteria:

          -  Diagnosis of any DSM-IV psychotic disorder

          -  History of drug or alcohol abuse or dependence in the preceding 3 months

          -  High suicide risk

          -  Clinically defined neurological disorder or insult

          -  Metal in the cranium or skull defects

          -  Skin lesions on the scalp (e.g. cuts, abrasions, rashes) at the proposed electrode
             sites

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Alonzo, BSc(Hons)/BA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales / Black Dog Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angelo Alonzo, BSc(Hons)/BA, PhD</last_name>
    <phone>+61-2-93822987</phone>
    <email>a.alonzo@unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Black Dog Institute</name>
      <address>
        <city>Randwick, Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>September 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of New South Wales</investigator_affiliation>
    <investigator_full_name>Colleen Loo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
